Drug intelligence / Profile preview

risperidone formulation in rumenic acid

Development stage: Phase 2
Lead developer: ValiSeek
Modality: Small Molecules
Administration: Oral

Overview

VAL401 is a reformulation of the established antipsychotic drug risperidone into a liquid-filled capsule containing rumenic acid. This special lipid formulation allows risperidone to enter cancer cells and inhibit the enzyme HSD10 (17HSD10), which is key to metabolism in cancerous cells. Unlike traditional risperidone that works at the cell surface for its anti-psychotic properties, VAL401's formulation enables the drug to penetrate cancer cells and disrupt their metabolic processes, breaking the cell cycle specifically in cancerous cells.

Targets

ABAD (17-beta-hydroxysteroid dehydrogenase type 10)

Beyond the preview

Go deeper on risperidone formulation in rumenic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on risperidone formulation in rumenic acid.

Explore the full profile